

## Data Dictionary for Data 1

Variable	Description
AchI	Acetylcholinesterase inhibitor use
AChR	Acetylcholine receptor antibody (positive/negative)
AChR.Level	Acetylcholine receptor antibody level
Age	Age at hospitalization
Age.max	Maximum of Age, Age.MG, Age.MY, and Age.TP
Age.MG	Age of MG onset
Age.MY	Age of myositis onset
Age.TP	Age of thymoma onset
Bplus	B+ blood type
Cardiac	Cardiac involvement (yes/no)
CD.comp	Whether $CD8 \geq CD4$
CD4	CD4 count
CD8	CD8 count
CK.level	Creatine kinase level
cort	Corticosteroid treatment
ct	Cardiovascular treatment
diagnose.thymoma	Diagnosis of thymoma (yes/no)
Earlier.onset	Indicates which occurred earlier: MG onset or myositis onset
Em	Endomysial infiltration
EMG	Electromyography (EMG) performed
EOMG	MG subtype: early-onset (EOMG) or late-onset (LOMG)
EOMG.45	Early-onset MG (onset < 45 years)
EOMG.50	Early-onset MG (onset < 50 years)
Eosinophils	Eosinophil infiltration
FN	Focal necrosis
GG	Presence of giant cells or granuloma
Giant.cells	Giant cells present
Granuloma	Granuloma present
group1	Group 1: Dermatomyositis Group 2: GCM/GrM, Polymyositis
group2	Group 1: CM/GrM, Polymyositis Group 2: Other, Dermatomyositis, OM
ICT	Increased connective tissue
IFSV	Increased fiber size variability
imm	Non-steroid immunomodulator use
ind.biopsy	Biopsy performed (yes/no)
Inflam	Inflammatory cell infiltration
Is	Interstitial infiltration
lag	Lag time between myositis and MG onset

*Continued on next page*

Variable	Description
MAA	Myositis-associated antibody (MAA) prevalence
macrophages	Macrophage infiltration
mEMG	Motor EMG results
MG.subtype	MG subtype classification
MSA	Myositis-specific antibody (MSA) prevalence
myocarditis	Myocarditis present
myositis.subtype	Myositis subtype classification
Oplus	O+ (+/-)
outcome	Clinical outcome
plasmapheresis	Plasmapheresis treatment
Pm	Perimysial infiltration
Pv	Perivascular infiltration
Regeneration	Muscle fiber regeneration
RNS	Repetitive nerve stimulation (RNS) performed
rs	Respiratory support
Sex	Sex of patient
SFEMG	Single-fiber EMG performed
Striated	Striational antibody (+/-)
TET	TET treatment
thymoma	Thymoma present
thymoma.subtype	Thymoma subtype classification
thymoma.type	Type of thymic tumor (thymoma/thymic carcinoma)
transaminitis	Transaminitis (elevated liver enzymes)
year	Year of case report

## Data Dictionary for Data 2

Variable	Description
AChR	Acetylcholine receptor (AChR) antibody status (+/âĀĲ).
AChR.level	AChR antibody level or titer (numeric).
abatacept	Abatacept treatment received (+/âĀĲ).
achl	Acetylcholinesterase inhibitor use (+/âĀĲ).
Age	Age at evaluation (years).
cancer	Broad cancer category (lung, melanoma, thymic, gastrointestinal, genitourinary, or other).
cancer.detailed	Detailed cancer diagnosis (e.g., thymic, lung, melanoma, gastrointestinal, genitourinary, or other).
Cardiac	Cardiac involvement (+/âĀĲ).
CD.comp	CD count comparison indicator (e.g., CD8 $\geq$ CD4).
CD4	CD4 lymphocyte count.
CD8	CD8 lymphocyte count.
CDB20	B-cell marker (CD20) presence or level.
complement	Complement deposition (+/âĀĲ).
confirm_diag	Confirmed diagnosis of myasthenia gravis (+/âĀĲ).
cort	Corticosteroids given (+/âĀĲ).
ct	Cardiovascular treatment (yes/no).
CTLA4	Anti-CTLA-4 monotherapy (+/âĀĲ).
CTLA4_PD1	Anti-CTLA-4 and PD-1/PD-L1 combination therapy (+/âĀĲ).
denova	De novo myasthenia gravis (+/âĀĲ).
derm	Dermatomyositis features present (+/âĀĲ).
dm	Definite myocarditis (+/âĀĲ).
Emp	Endomysial inflammation or pathology (+/âĀĲ).
ff	Fatigable or fluctuating muscle weakness (+/âĀĲ).
FN	Focal necrosis on muscle biopsy (+/âĀĲ).
GG	Giant cells or granuloma present (+/âĀĲ).
HP	Hepatitis (+/âĀĲ).
IC	Inflammatory cell infiltration (+/âĀĲ).
ICT	Increased connective tissue or fibrosis (+/âĀĲ).
IFSV	Increased fiber size variability (+/âĀĲ).
igg	IgG deposition or serum IgG level (specify units).
imm	Non-steroid immunomodulator use (yes/no).
inflam.myopathy	Inflammatory myopathy subtype or classification (+/âĀĲ).
interval	Time interval between diagnoses or events (specify units).
ip	Interstitial pathology (+/âĀĲ).
Isp	Interstitial space involvement (+/âĀĲ).
LRP4	Anti-LRP4 antibody status (+/âĀĲ).
Macrophages	Macrophage infiltration on biopsy (+/âĀĲ).

*Continued on next page*

Variable	Description
mEMG	Motor EMG abnormality (+/âĀĲ).
MG	Myasthenia gravis diagnosis (+/âĀĲ).
MG.PD	Prior history of myasthenia gravis (+/âĀĲ).
mg.type	MG subtype (e.g., MG alone; MG with myositis or myocarditis).
mgmm	MG with myositis and/or myocarditis (+/âĀĲ).
MGS	Myasthenia gravisâĀĲlike syndrome (+/âĀĲ).
mhc1	MHC-I upregulation on muscle fibers (+/âĀĲ).
mhc2	MHC-II expression (+/âĀĲ).
MR	Myositis/rhabdomyolysis (+/âĀĲ).
msa	Myositis-specific antibody status (+/âĀĲ).
muscle.biopsy	Muscle biopsy grouping (Group 1: myositis alone; Group 2: myocarditis alone; Group 3: myositis with myocarditis).
musk	Anti-MuSK antibody status (+/âĀĲ).
mwm	Myositis with myocarditis (+/âĀĲ).
myocarditis	Myocarditis (+/âĀĲ).
myositis.subtypes.other	Myositis subtype: dermatomyositis; myocarditis (only C); or myositis (no D).
myositis.subtypes.other2	Myositis subtype: myocarditis (only C); myositis (no D and no C); or myositis with myocarditis.
non.derm.IBM	Non-dermatomyositis inclusion body myositis (IBM) indicator (+/âĀĲ).
Op	O <sup>+</sup> blood type (+/âĀĲ).
outcome	Clinical outcome (e.g., improved, stable, worsened).
pck	Peak creatine kinase level (numeric).
pd	Pre-existing or de novo myasthenia gravis (+/âĀĲ).
PD1	Anti-PD-1/PD-L1 monotherapy (+/âĀĲ).
pd11	PD-L1 biomarker positivity (+/âĀĲ).
plasma	Plasma cell infiltration (+/âĀĲ).
plasmapheresis	Plasmapheresis performed (+/âĀĲ).
pm	Probable myocarditis (+/âĀĲ).
pm2	Possible myocarditis (+/âĀĲ).
Pmp	Perimysial infiltration or pathology (+/âĀĲ).
pt	Peak troponin level (numeric).
Pvp	Perivascular infiltration or pathology (+/âĀĲ).
Regeneration	Muscle fiber regeneration (+/âĀĲ).
rns	Repetitive nerve stimulation (RNS) abnormality (+/âĀĲ).
rs	Respiratory support required (+/âĀĲ).
sem	SMEMG/EMG abnormality (+/âĀĲ).
Sex	Sex (F/M).
sfemg	Single-fiber EMG abnormality (+/âĀĲ).
Striated	Striational antibody (+/âĀĲ).

*Continued on next page*

Variable	Description
treatment	Specific treatment(s) received (CTLA-4, PD-1 & CTLA-4, PD1/PDL1).

## Data Dictionary for Data 3

Variable	Description
Age	Age
Cardiac	Cardiac involvement (+/-)
CK	Creatine kinase (+/-)
CK.level	Creatine kinase level
cort	Corticosteroid treatment
ct	Cardiovascular treatment
Diagnosis.Thymoma	Diagnosis of thymoma
imm	Non-steroid immunomodulator use
MSA	Myositis-specific antibody (MSA) prevalence
myositis	Myositis categories (DM/GCM/PM)
Op	O+ (+/-)
outcome	Clinical outcome
plasmapheresis	Plasmapheresis treatment
rs	Respiratory support
Sex	Sex
Striated	Striational antibody (+/-)

## Data Dictionary for Data 4

Variable	Description
Age	Age at presentation/diagnosis
Sex	Sex of patient
Cause	Cause leading to discovery of thymoma
who.subtype	WHO thymic epithelial tumor (thymoma) subtype (A, AB, B1–B3, C)
Clinical.MG	Clinical myasthenia gravis status or phenotype (e.g., yes/no, generalized/ocular)
AChR	Acetylcholine receptor antibody status (positive/negative)
Local.Symptoms	Local symptoms (Existent/None)
bsize	Maximum dimension of size (before)
Hemorrhage	Intratumoral hemorrhage present (yes/no)
Necrosis	Tumor necrosis present (yes/no)
Cyst	Cystic change present (yes/no)
Fibrosis	Fibrosis present on pathology/imaging (yes/no)
Pleural.Effusion	Pleural effusion present (yes/no)
Masaoka.Stage	Masaoka stage (I/II/III)
duration	Follow up period duration (months)
recurrence	Thymoma recurrence during follow up period (yes/no)
change	Change of size
interval	Time interval